Drugs / Low dose IL-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05902520 | Jun 2023 → Dec 2026 expected | colorectal cancer, female reproductive organ cancer, head and neck squamous cell carcinoma, lung cancer +2 | AgonOx, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Low dose IL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05902520 ↗ |
| Route | Subcutaneous | “delivered subcutaneously for 1, 2 or 3 weeks” NCT05902520 ↗ |